- Open Access
Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site
Retrovirology volume 11, Article number: 32 (2014)
The CD4 binding site (CD4bs) of envelope glycoprotein (Env) gp120 is a functionally conserved, important target of anti-human immunodeficiency virus type 1 (HIV-1) neutralizing antibodies. Two neutralizing human monoclonal antibodies, IgG1 b12 (b12) and VRC01, are broadly reactive neutralizing antibodies which recognize conformational epitopes that overlap the CD4bs of Env gp120; however, many CRF01_AE viruses are resistant to neutralization mediated by these antibodies. We examined the mechanism underlying the b12 resistance of the viruses using CRF01_AE Env (AE-Env)-recombinant viruses in this study.
Our results showed that an amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env-recombinant viruses by cooperating with 2 previously reported potential N-linked glycosylation (PNLG) sites at positions 186 (N186) and 197 (N197) in the V2 and C2 regions of Env gp120. The amino acid residue at position 185 and 2 PNLG sites were responsible for the b12 resistance of 21 of 23 (>91%) AE-Env clones tested. Namely, the introduction of aspartic acid at position 185 (D185) conferred b12 susceptibility of 12 resistant AE-Env clones in the absence of N186 and/or N197, while the introduction of glycine at position 185 (G185) reduced the b12 susceptibility of 9 susceptible AE-Env clones in the absence of N186 and/or N197. In addition, these amino acid mutations altered the VRC01 susceptibility of many AE-Env clones.
We propose that the V2 and C2 regions of AE-Env gp120 contain the major determinants of viral resistance to CD4bs antibodies. CRF01_AE is a major circulating recombinant form of HIV-1 prevalent in Southeast Asia. Our data may provide important information to understand the molecular mechanism regulating the neutralization susceptibility of CRF01_AE viruses to CD4bs antibodies.
The envelope glycoproteins (Env), gp120 and gp41, of human immunodeficiency virus type 1 (HIV-1) play a central role in viral transmission and mediate attachment and incorporation of the virus into target cells through specific interactions with the CD4 receptor and chemokine co-receptors . In addition, Env is the major target of anti-HIV-1 neutralizing antibodies and, in particular, the CD4 binding site (CD4bs) of Env gp120 is a functionally conserved, important target of neutralizing antibodies [2–7].
Although numerous monoclonal antibodies against HIV-1 Env have been developed, a limited number of broadly reactive neutralizing human monoclonal antibodies (nhmAbs) have been established [8–11]. Two nhmAbs, IgG1 b12 (b12) and VRC01, are potent and broadly reactive neutralizing antibodies which recognize conformational epitopes that overlap the CD4bs of HIV-1 Env gp120 [5, 7, 12–14]. The nhmAb, b12 was established from a Fab (IgG1κ) phage display library generated from a bone marrow sample from an HIV-1-infected patient [12, 15], and is able to neutralize diverse strains of HIV-1 [16, 17]. In addition, b12 protects hu-PBL-SCID mice and macaque monkeys from infection with HIV-1 and a chimeric simian-human immunodeficiency virus (SHIV), respectively [18–20]. Moreover, adeno-associated virus vector-mediated gene transfer of the b12 gene protected humanized mice from HIV infection . VRC01 is a potent and broadly reactive nhmAb established from an HIV-1-infected patient, and is capable of neutralizing diverse HIV-1 strains . VRC01 inhibits HIV-1 infection in RAG-hu (SCID mice injected with human hematopoietic stem cells) mice  and hCD4/R5/cT1 (transgenic mice carrying the gene encoding human CD4, CCR5 and cyclin T1) mice . It has been demonstrated that serum antibodies specific for the CD4bs of Env gp120 are responsible for the potent and broad neutralization of HIV-1 strains mediated by broadly reactive sera of HIV-1-infected patients ; therefore, it is important to establish a vaccine strategy to elicit broadly neutralizing antibodies against CD4bs, such as b12 and VRC01 [3, 5, 24]. To this end, the regulatory mechanisms underlying the susceptibilities of various HIV-1 strains to CD4bs antibodies, b12 and VRC01, need to be clarified.
CRF01_AE is a major circulating recombinant form (CRF) of HIV-1 prevalent throughout Southeast Asia . In particular, CRF01_AE is responsible for more than 80% of infection cases in Thailand . Although b12 is able to broadly neutralize HIV-1 subtypes B, C and D clinical isolates, it poorly neutralizes many CRF01_AE strains [5, 16, 27, 28]. In addition, although VRC01 neutralizes 89% of CRF01_AE strains, the remaining 11% of the viruses are resistant to VRC01-mediated neutralization . The mechanisms of how CRF01_AE viruses show low susceptibility or are resistant to neutralization by b12 and VRC01 are still not fully understood, and such studies are still ongoing [29–31]. Recently, we established a series of CRF01_AE Env (AE-Env)-recombinant viruses  and studied their neutralization susceptibility to nhmAbs including b12 [27, 32]. Our study revealed that 2 potential N-linked glycosylation (PNLG) sites at amino acid positions 186 and 197, designated as N186 and N197 (amino acid numbering is based on the Env amino acid sequence of a reference strain, HXB2 [Genbank: K03455]), in the V2 and C2 regions of AE-Env gp120 play an important role in regulating the b12 susceptibility of AE-Env-recombinant viruses . However, many AE-Env-recombinant viruses tested were still resistant to b12-mediated neutralization; therefore, we examined further the mechanism underlying the b12 resistance of AE-Env-recombinant viruses in this study.
PNLG sites at amino acid positions 301, 339, 386 and 392 of Env gp120 play no major role in the b12 susceptibility of AE-Env-recombinant viruses
Our previous study showed the important role of 2 PNLG sites, N186 and N197, in the V2 and C2 regions of Env gp120 in regulating the b12 susceptibility of AE-Env-recombinant viruses . Although most AE-Env-recombinant viruses tested were originally b12 resistant, the removal of N186 and/or N197 conferred b12 susceptibility to approximately 47% (15 of 32) of the recombinant viruses (Table 1). However, it was not possible to confer b12 susceptibility to the remaining 53% (17 of 32) of AE-Env-recombinant viruses (Table 1), indicating that other factors besides N186 and N197 are involved in the b12 resistance of AE-Env-recombinant viruses. Therefore, we searched for other determinants of the b12 susceptibility of AE-Env-recombinant viruses in this study. First, we compared the amino acid sequences involved in or in close proximity to the b12 contact sites of gp120, based on a previous report by Wu et al. , between 2 groups of AE-Env clones. One group consisted of 15 AE-Env clones which became b12 susceptible after removing N186 and/or N197, whereas the other group consisted of 17 AE-Env clones which were still resistant to b12 after removing these PNLG sites (Table 1). We found that 15 b12-susceptible AE-Env clones contained PNLG sites less frequently at amino acid positions 301 (N301), 339 (N339) and 392 (N392) of gp120 than 17 b12-resistant clones (Table 2). It was reported that N301 and a PNLG site at position 386 (N386) act as a glycan shield against neutralizing antibodies and may confer an advantage for transmission of CRF01_AE viruses from mother to infant . In addition, N301, N339, N386 and N392 are involved in reducing the b12 susceptibility of subtype B Env (B-Env) [35–38]. Therefore, we examined the possible involvement of these PNLG sites in regulating the b12 susceptibility of AE-Env-recombinant viruses. To this end, a series of AE-Env mutants in which amino acid substitutions were introduced into these residues was prepared and tested their b12 susceptibility. The results showed that the introduction of amino acid substitutions into these PNLG sites did not improve the b12 susceptibility of selected AE-Env clones, 21PL2, 22PL1, 50PB2, 98CC2 and 104PB4 (Figure 1). In addition, the mutations, N339Q and N386Q, rather slightly reduced the b12 susceptibility of an AE-Env clone, 98CC2 (Figure 1D). Therefore, we concluded that these PNLG sites played no major role in regulating the b12 susceptibility of AE-Env clones.
A single amino acid substitution in the V2 region of gp120 significantly alters the b12 susceptibility of recombinant viruses containing AE-Env clones, 47CC11 and 47PL1
Among 32 AE-Env clones, 2 AE-Env clones, 47PL1 and 47CC11, showed distinct neutralization susceptibility to b12 after the removal of N197 (Table 1), although these AE-Env clones were derived from an HIV-1-infected individual and showed a close phylogenetic relationship . Namely, a recombinant virus containing 47PL1-N197Q (amino acid substitution from asparagine [N] to glutamine [Q] at position 197 in HXB2 numbering) was highly susceptible to b12 [50% inhibitory concentration (IC50) = 0.03 μg/ml], whereas the recombinant virus containing 47CC11-N197Q was resistant to b12-mediated neutralization (Table 1). In order to search for the determinants of b12 susceptibility, we compared the amino acid sequences of Env gp120 between 47PL1 and 47CC11. Ten positions were found to be different between b12-susceptible 47PL1 and b12-resistant 47CC11 (Figure 2, asterisks). Therefore, a series of point mutations, H144L, G185D, N189S, I190T, N301Q, I467T, V488I, R500M, del.NIND (deletion of 4 amino acid residues, NIND in the V2 region of gp120) (Figure 2) or ins.D460 (insertion of an amino acid residue D460) was introduced into 47CC11-N197Q, and recombinant viruses containing these AE-Env mutants were subjected to neutralization tests. The results showed that a recombinant virus containing 47CC11-G185D/N197Q became highly susceptible to b12 (IC50 = 0.03 μg/ml), whereas the 9 remaining 47CC11-N197Q-derived mutants were b12 resistant, similar to 47CC11-N197Q (Figure 3A). In addition, a mutant AE-Env clone, 47CC11-G185D, was constructed and subjected to neutralization tests. A recombinant virus containing 47CC11-G185D was moderately susceptible to b12-mediated neutralization (IC50 = 7.62 μg/ml), although the extent of b12 susceptibility was lower than that of 47CC11-G185D/N197Q (IC50 = 0.03 μg/ml) (Figure 3A). These results showed that an amino acid substitution, G185D, conferred b12 susceptibility to an AE-Env clone, 47CC11. In order to confirm the role of the amino acid substitution at position 185 in viral neutralization susceptibility to b12, a mutation, D185G, was introduced into 47PL1-N197Q, a b12-susceptible AE-Env mutant, and its effect on viral b12 susceptibility was tested. The result showed that a recombinant virus containing 47PL1-D185G/N197Q became b12 resistant, similar to the wild type of 47PL1 (Figure 3B). These results show that the amino acid residue at position 185 in the V2 region of gp120 plays an important role in determining the b12 susceptibility of 2 AE-Env clones, 47CC11 and 47PL1. Namely, aspartic acid (D185) and glycine (G185) residues at amino acid position 185 were responsible for the b12 susceptibility and resistance of 47PL1 and 47CC11, respectively.
Comparison of amino acid residue at position 185 of Env gp120 among subtype B, subtype C and CRF01_AE viruses
We next studied the amino acid residue at position 185 of gp120 among HIV-1 subtype B, subtype C and CRF01_AE viruses, which were retrieved from the HIV sequence database. The results showed that 70.5% of B-Env clones, and 19% and 24% of subtype C Env (C-Env) and AE-Env clones, respectively, contained D185 (Table 3). In addition, a variation was observed in the amino acid residue at position 185 of gp120 among C-Env and AE-Env clones (Table 3). The majority of AE-Env clones contained D185 (24%), glutamic acid (E185) (27.5%), G185 (22%) or asparagine (N185) (16%) at position 185 of gp120 (Table 3). In addition, among our 32 AE-Env clones, D185 was conserved in 66.7% (10 of 15) of the clones which were b12 susceptible in the absence of N186 and/or N197, while G185, N185 or E185 was contained in 64.6% (11 of 17) of AE-Env clones which were resistant to b12 after removing N186 and/or N197 (Table 3).
The impact of the amino acid residue at position 185 of gp120 on the b12 susceptibility of AE-Env-recombinant viruses
We examined the role of the amino acid residue at position 185 in the b12 susceptibility of 3 selected AE-Env-recombinant viruses. The recombinant virus containing an AE-Env clone, 52PL7, was b12 resistant even after removing N186 and N197 (Figure 4A), while the recombinant viruses containing 62PL1 and 101PL1 became b12 susceptible at a low level after removing N186 and N197 (Figure 4B and C). However, the introduction of an amino acid substitution, E185D (Figure 4A), G185D (Figure 4B) or N185D (Figure 4C), conferred b12 susceptibility to AE-Env mutants or markedly improved their b12 susceptibility. Namely, the introduction of E185D conferred b12 susceptibility to an AE-Env clone, 52PL7-N186Q/N197Q (Figure 4A, 52PL7-E185D/N186Q/N197Q), while a mutation, G185D or N185D markedly improved the b12 susceptibility of 2 AE-Env clones, 62PL1-N186Q/N197Q (Figure 4B, 62PL1-G185D/N186Q/N197Q) and 101PL1-N186Q/N197Q (Figure 4C, 101PL1-N185D/N186Q/N197Q). In addition, although the single amino acid substitution, G185D, conferred b12 susceptibility to the wild type of 62PL1 (Figure 4B, 62PL1-G185D) (IC50 = 8.26 μg/ml), the extent of b12 susceptibility was further improved by multiple amino acid substitutions generating the mutants 62PL1-G185D/N186Q (IC50 = 2.32 μg/ml), 62PL1-G185D/N197Q (IC50 = 0.04 μg/ml) and 62PL1-G185D/N186Q/N197Q (IC50 = 0.01 μg/ml) (Figure 4B). These results suggested that 2 PNLG sites, N186 and N197, and the amino acid residue at position 185 synergistically regulated the b12 susceptibility of AE-Env clones.
We further examined the role of the amino acid residue at position 185, N186 and N197 on the b12 susceptibility of AE-Env clones using recombinant viruses, and the results are summarized in Tables 4 and 5. In addition, the relative infectivity of recombinant viruses containing wild-type or mutant AE-Env clones is shown in Tables 6 and 7. Most recombinant viruses containing mutant AE-Env clones maintained their infectivity, while some recombinant viruses lost their infectivity after the introduction of mutations (Tables 6 and 7). The wild types of 14 AE-Env clones, 21PL2, 47CC11, 50PB2, 52PB3, 52PL4, 52PL7, 60PB2, 60PL2, 62PL1, 65CC4, 98CC2, 101PL1, 102CC2 and 104PB4, were b12 resistant, and these AE-Env clones were still b12 resistant or showed comparably low levels of b12 susceptibility in the absence of N186 and/or N197; however, the introduction of an amino acid substitution, G185D, N185D or E185D, to these AE-Env mutants lacking N186 and/or N197, except 60PL2- and 104PB4-derived mutants, markedly improved their b12 susceptibility (Table 4). In addition, the removal of N186 and/or N197 conferred b12 susceptibility to 9 b12-resistant AE-Env clones, 29CC1, 45CC1, 47PL1, 99PB2, 99CC8, 105PB1, 105PL2, 105PL3 and 107CC2; however, the introduction of an amino acid substitution, D185G, to those AE-Env mutants lacking N186 and/or N197 transformed them into b12-resistant or low-susceptible mutants (Table 5). In addition, the introduction of a mutation, D185N or D185E, altered the b12 susceptibility of selected AE-Env clones, 29CC1, 45CC1, 47PL1, 105PB1 and 105PL3, to a lesser extent than the alteration by the introduction of D185G to the corresponding AE-Env clones (Table 5). These results suggested that D185 is responsible for the b12 susceptibility of AE-Env clones, while G185, N185 and E185 are responsible to a different extent for b12 resistance or the low susceptibility of AE-Env clones. Taking together the results shown in Figures 3 and 4 as well as in Tables 4 and 5, it is demonstrated that the amino acid residue at position 185 in the V2 region of gp120 plays a crucial role in the b12 resistance of AE-Env clones by cooperating with 2 PNLG sites, N186 and N197.
Correlation between the binding efficiency and neutralization susceptibility of AE-Env-recombinant viruses to b12
In our previous report, it was suggested that the N-linked glycosylation of amino acid residues at positions 186 and 197 of gp120 inhibited the binding of b12 to gp120 molecule in a computational model of the trimeric structure of HIV-1 Env proteins . In order to study the mechanism of how a single amino acid substitution at the position 185 of gp120 regulated the b12 susceptibility of AE-Env clones, we tested the binding efficiency of b12 to AE-Env proteins on viral particles. The results showed that low or no binding of b12 to the wild-type Env proteins of three selected AE-Env clones, 47CC11, 50PB2 and 52PB3, was observed (Figure 5, closed bars). In contrast, the introduction of a single mutation, G185D or N197Q, somewhat improved the binding efficiency of b12 to these AE-Env proteins relative to the corresponding wild-type proteins (Figure 5, left hatched or open bars, respectively), while the introduction of double mutations, G185D, N185D or E185D (GNE185D), together with N197Q significantly improved the binding of b12 to AE-Env proteins (Figure 5, right hatched bars). A relative correlation was observed between the b12 binding efficiency (Figure 5) and the b12 susceptibility of AE-Env clones in each set of wild-type and mutant clones (Figure 3A and Table 4). These results suggested that the amino acid residue at position 185 regulated the b12 susceptibility of AE-Env clones at the level of the binding of b12 to Env proteins.
The amino acid residue at position 185 of gp120 does not affect the b12 susceptibility of 5 B-Env-recombinant viruses, while the removal of a PNLG site, N186 or N197, improves the b12 susceptibility of 4 B-Env-recombinant viruses
We next examined the role of amino acid residue at position 185 and 2 PNLG sites, N186 and N197, of gp120 in regulating the b12 susceptibility of 5 B-Env-recombinant viruses. Four recombinant viruses containing the wild-type Env of pNL4-3, QH0692.42, SC422661.8 and pWITO4160.33, were b12 susceptible, while a recombinant virus containing that of TRO.11 was b12 resistant (Figure 6). In addition, the wild-type Env of pNL4-3, QH0692.42 and SC422661.8 contained D185, while that of pWITO4160.33 and TRO.11 contained E185 (data not shown). Moreover, the wild-type Env of pNL4-3 contained N186 and N197, while that of QH0692.42, SC422661.8, pWITO4160.33 and TRO.11 contained N197, but not N186 (data not shown). We introduced an amino acid substitution at position 185; however, the b12 susceptibility of B-Env clones was not significantly altered by the introduction of the mutation (Figure 6). In contrast, the removal of N186 improved the b12 susceptibility of pNL4-3 (Figure 6A), while the removal of N197 improved the b12 susceptibility of pNL4-3, QH0692.42, SC422661.8 and pWITO4160.33 (Figure 6A, B, C and D), but not of TRO.11 (Figure 6E). In addition, the introduction of double mutations, E185D and N197Q, did not confer b12 susceptibility to TRO.11 (Figure 6E), while the introduction of double mutations, D185G and N197Q, did not alter the b12 susceptibility of QH0692.42 and SC422661.8, relative to the introduction of a single mutation, N197Q, into these B-Env clones (Figure 6B and C). Finally, mutant B-Env clones, pNL4-3-N186Q/N197Q, pNL4-3-D185G/N197Q and pWITO4160.33-E185D/N197Q were also constructed; however, recombinant viruses containing these B-Env mutants showed no infectivity (Table 8); therefore, we failed to test their b12 susceptibility. These results suggested that the amino acid residue at position 185 of gp120 played no major role in the b12 susceptibility of B-Env clones. In addition, 4 of 5 wild-type B-Env clones were already highly susceptible to b12 in the presence of N186 and/or N197 (Figure 6A, B, C and D), while the removal of N197 did not confer b12 susceptibility to TRO.11 (Figure 6E). Therefore, we consider that, although 2 PNLG sites, N186 and N197, of gp120 play an important role in regulating the b12 susceptibility of B-Env clones, the role for these B-Env clones is not as significant as that for AE-Env clones tested.
Role of the amino acid residue at position 185, N186 and N197 in the VRC01 susceptibility of AE-Env-recombinant viruses
We next examined the role of the amino acid residue at position 185, as well as of 2 PNLG sites, N186 and N197, in the susceptibility of AE-Env-recombinant viruses to VRC01-mediated neutralization. VRC01 has been reported to be capable of neutralizing 89% of CRF01_AE viruses tested ; however, among selected AE-Env clones tested, the wild types of 56.5% (13 of 23) of AE-Env clones, 29CC1, 45CC1, 47PL1 and 105PL2 (Table 9) as well as 21PL2, 47CC11, 52PB3, 52PL4, 52PL7, 60PL2, 62PL1, 102CC2 and 104PB4 (Table 10), were VRC01 resistant, while those of 43.5% (10 of 23) of AE-Env clones, 99PB2, 99CC8, 105PB1, 105PL3 and 107CC2 (Table 9), as well as 50PB2, 60PB2, 65CC4, 98CC2 and 101PL1 (Table 10), were susceptible to VRC01-mediated neutralization. In addition, the VRC01 susceptibility of AE-Env clones, 45CC1, 99CC8, 105PL2, 105PL3 and 107CC2 (Table 9), as well as 21PL2, 50PB2, 52PB3, 52PL4, 60PB2, 60PL2, 65CC4, 98CC2, 101PL1 and 102CC2 (Table 10), was improved after the removal of N186 and/or N197, suggesting that 2 PNLG sites, N186 and N197, played a role in regulating the VRC01 susceptibility of some AE-Env clones tested. We next studied the role of the amino acid residue at position 185 in the VRC01 susceptibility of AE-Env clones. The results showed that the introduction of a mutation, D185G, to most AE-Env mutants lacking N186 or N197, except 45CC1- and 105PL2-derived mutants, did not reduce the VRC01 susceptibility of AE-Env clones (Table 9), suggesting that the amino acid residue at 185 had no major role in the VRC01 susceptibility of these AE-Env clones. However, the introduction of a mutation, G185D, N185D or E185D, to the AE-Env clones lacking N186 and/or N197 improved the VRC01 susceptibility of AE-Env clones, 21PL2, 50PB2, 52PB3, 52PL4, 60PB2 and 102CC2 (Table 10), while the introduction of the mutation did not affect significantly or rather reduced the VRC01 susceptibility of the remaining AE-Env clones, 47CC11, 52PL7, 60PL2, 62PL1, 65CC4, 98CC2, 101PL1 and 104PB4 (Table 10). These results suggested that the amino acid residue at position 185, as well as 2 PNLG sites, N186 and N197, regulated the susceptibility of some AE-Env clones to VRC01-mediated neutralization; however, their role in VRC01 susceptibility is not as significant as that for the b12 susceptibility of AE-Env clones.
Amino acid mutations and N-linked glycosylation of particular amino acid residues affect the protein structure and change the neutralization susceptibility of HIV-1 Env [39, 40]. Although several reports describe the role of PNLG sites involved in or in close proximity to the b12 contact sites of gp120 in regulating the b12 susceptibility of subtype B viruses [31, 34–38], the PNLG sites, N301, N339, N386 and N392, had no major role in the b12 susceptibility of AE-Env-recombinant viruses (Figure 1). We therefore searched for other determinants of the b12 resistance of AE-Env clones using recombinant viruses and found that a single amino acid substitution at position 185 in the V2 region of gp120 played a crucial role in regulating the b12 susceptibility of AE-Env clones by cooperating with two previously reported PNLG sites, N186 and N197, in the V2 and C2 regions of gp120 . These amino acid positions were responsible for determining the b12 resistance of 21 of 23 (>91%) AE-Env clones tested. The V1/V2 regions of gp120 contact with CD4 molecule when gp120 binds to CD4 [41, 42], and this may account for the role of V1/V2 regions in regulating viral susceptibility to neutralizing antibodies against the CD4bs of gp120, including b12 [35, 43–46]. Previous computational analysis revealed that the amino acid residue at position 185 was involved in the regulation of viral b12 susceptibility . The amino acid residue at position 185 locates near the C-terminus of V2 region, where the amino acid sequence is relatively conserved and affects the interaction of b12 with gp120 molecule [29, 41, 47]. In the report, G185 was suggested to be responsible for viral b12 resistance among several subtypes and CRFs of HIV-1, while D185, E185 or N185 of gp120 were responsible for viral b12 susceptibility . Our results demonstrated the role of G185 in viral b12 resistance; however, they were partly inconsistent with the previous report. Namely, the effect of E185 and N185 on viral b12 susceptibility was not as significant as that of D185 in our study; therefore, there is a discrepancy between our biological and previous computational analyses.
Our previous report showed that high amino acid variability was observed in the V2 region, as well as in the V1, V4 and V5 regions, of Env gp120 among viral genomic fragments continuously collected for a short period (3 years) from CRF01_AE-infected Thai individuals , suggesting that the virus constantly evolved by introducing mutations in the V2 region of gp120, presumably in order to counteract anti-HIV-1 humoral immune responses. Env gp120 and gp41 are the major targets of anti-HIV-1 neutralizing antibodies, and are therefore candidates for vaccine antigens. Although an HIV vaccine has been under development for more than two decades, no effective vaccine is available . Until recently, only one completed clinical trial in Thailand, RV144, was shown to have 31.2% protection efficacy against HIV-1 infection [49–51]. The recombinant Env gp120 protein derived from a CRF01_AE (A244) strain, A244-rgp120, and that derived from a subtype B (MN) strain, MN-rgp120, were used as immunogens in the RV144 clinical trial  and the majority of HIV-1 infection in the trial was caused by CRF01_AE viruses (91.7%) , which are the predominant CRF of HIV-1 prevalent in Thailand . Recent analyses of the vaccine-induced immune responses in the RV144 trial showed that the induction level of antibodies against the V2 region of Env gp120 was inversely correlated with the infection risk [54–56]. In addition, antibodies against the V2 region recognized both a conformational epitope presented on a fusion protein containing the V1 and V2 regions of gp120, gp70-V1V2, as well as a linear epitope located at amino acid residues 165-178 in the V2 region , while a lysine residue at position 169 (K169) and an isoleucine residue at position 181 (I181) in the V2 region played an important role in determining vaccine efficacy . These studies suggest that immunodominant regions located in the V2 region of Env gp120 are an effective target of protective immune response against CRF01_AE viruses, and the introduction of mutations into a few amino acid residues in the V2 region significantly affect the effectiveness of vaccine-induced anti-V2 neutralizing antibodies. Our study revealed that the major determinants of resistance to a CD4bs antibody, b12, were located in the V2 region of Env gp120 derived from CRF01_AE viruses. Therefore, we believe that further understanding of how amino acid mutations in the V2 region of Env gp120 affect the neutralization susceptibility of currently circulating CRF01_AE viruses to vaccine candidate-induced neutralizing antibodies as well as to established broadly reactive nhmAbs may provide important information to develop effective HIV-1 vaccines.
Our recent study showed that plasma samples derived from infected Thai individuals efficiently neutralize AE-Env-recombinant viruses, while the samples poorly neutralized B-Env- and C-Env-recombinant viruses , consistent with the results described in a previous report that serum samples derived from subtypes B and E (CRF01_AE)-infected Thai individuals showed subtype-specific neutralizing activity . These results suggest a difference in the antigenicity of Env gp120 and gp41 among CRF01_AE, subtype B and C viruses. In addition, the AE-Env immunogen, A244-rgp120, is suggested to be able to induce a stronger antibody response against the V2 region than the B-Env immunogen, MN-rgp120, in the RV144 trial [55, 60]; therefore, the immunogenicity of the V2 region of Env gp120 might also differ between CRF01_AE and subtype B viruses. Env gp120 is the most variable HIV-1 protein with typical intersubtype and intrasubtype differences soaring to 35% and 20%, respectively . In addition, structural differences of the conserved and variable regions of Env gp120 are reported between subtype B and C Env molecules [62, 63], while our previous study suggested that different Env regions are affected by host immune pressure between CRF01_AE and subtype B viruses . Therefore, the structure of Env gp120 is somewhat different among diverse HIV-1 subtypes and CRFs. The b12 antibody recognizes a conformational epitope on gp120; thus, b12 susceptibility of the virus is necessarily affected by the protein structure of gp120. Our results showed that the amino acid residue at position 185 in the V2 region of Env gp120 played a major role in b12 susceptibility of AE-Env clones, but not of B-Env clones, suggesting that the structure of the V2 region may differ between CRF01_AE and subtype B viruses. Although the structure of the V2 region of Env gp120 derived from subtype C viruses is already determined , that of CRF01_AE has not been determined; therefore, we consider that it is important to solve the protein structure of AE-Env gp120 in order to design an effective vaccine antigen against CRF01_AE viruses. Since the structure of AE-Env gp120 including the V2 region is currently not available, it is difficult to discuss the structural aspects of the role of the amino acid residue at position 185 and 2 PNLG sites, N186 and N197, in regulating the b12 susceptibility of AE-Env clones; however, the potential effects of these amino acid substitutions on Env structure is as follows. According to the structural studies on BG505 SOSIP.664 gp140 derived from a subtype A strain, BG505, the glycan attached at the position 197 of gp120 contacts with the V3 region of neighboring gp120 molecule in Env trimeric structure, and is suggested to avoid the premature release of V3 region before the binding of gp120 to CD4 . In addition, the removal of N197 from subtypes B and C Env proteins is reported to increase viral susceptibility to neutralizing antibodies including b12 [31, 35, 43, 66, 67], and this may be due to the changing in the quaternary structure of Env trimmers which leads to increase the accessibility of antibodies to the epitopes. The removal of N197 might reduce the stability of CD4-unbounded Env proteins and possibly decreases viral infectivity. However, the removal of N186 and N197, as well as the introduction of a mutation at amino acid position 185, did not significantly reduce the infectivity of most AE-Env-recombinant viruses (Tables 6 and 7), indicating that these AE-Env clones maintained the functional Env structure in the presence of these mutations. However, the binding of b12 to AE-Env proteins was significantly improved by the introduction of double mutations, G185D, N185D or E185D together with N197Q, but not by the introduction of a single mutation, N197Q or G185D (Figure 5). By considering these results, the introduction of an amino acid substitution at position 185 and the removal of N197 might synergistically alter the trimeric structure of AE-Env proteins and lead to increase the binding efficiency of b12 to Env proteins. We believe that our results might provide important information to take into account the antigenic and immunogenic diversity of Env gp120 among different subtypes and CRFs of HIV-1 to develop an effective HIV-1 vaccine.
In this report, we show that the amino acid residue at position 185 and 2 PNLG sites in the V2 and C2 regions of AE-Env gp120 are the major determinants of viral resistance to CD4bs antibodies. We believe that our data may provide important information to understand the molecular mechanism regulating the neutralization susceptibility of HIV-1 CRF01_AE viruses to CD4bs antibodies as well as to design vaccine antigens against these viruses.
293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum (10% FBS-DMEM). U87.CD4.CCR5 and U87.CD4.CXCR4 cells were obtained from Drs. HongKui Deng and Dan R. Littman through the AIDS Research and Reference Reagent Program (ARRRP) (Division of AIDS, NIAID, NIH), and were maintained in 10% FBS-DMEM with puromycin (1 μg/ml) and G418 (300 μg/ml) (complete medium).
Preparation of recombinant proviral constructs
cDNAs encoding full-length AE-Env gp120 and gp41 were cloned into pNL-envCT , a luciferase reporter proviral DNA derived from pNL4-3 , to generate AE-Env-recombinant proviral constructs as described previously . In addition, full-length subtype B env clones, QH0692.42, TRO.11, pWITO4160.33 and SC422661.8 , obtained from Drs. Feng Gao, Beatrice H. Hahn, Ming Li, David C. Montefiori and Jesus F. Salazar-Gonzalez through the ARRRP, were cloned into pNL-envCT to generate B-Env-recombinant proviral constructs as described previously . In order to generate N-linked glycosylation mutants, N186Q, N197Q, N301Q, N339Q, N386Q and/or N392Q, were introduced into proviral constructs by site-directed mutagenesis using the QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). In addition, single or multiple amino acid mutation(s), H144L, D185G, D185N, D185E, G185D, N185D, E185D, del.NIND (deletion of 4 amino acid residues, NIND), N189S, I190T, ins.D460 (insertion of D460), I467T, V488I and/or R500M, were introduced into proviral constructs by site-directed mutagenesis.
Detection of PNLG site in the deduced amino acid sequence of HIV-1 envgene
PNLG sites in HIV-1 env genes were examined using N-Glycosite (http://www.hiv.lanl.gov).
Preparation of recombinant virus
Viral supernatant was prepared by transfecting 293 T cells with a proviral construct using FuGENE HD transfection reagent (Roche, Basel, Switzerland). Forty-eight hours after transfection, the supernatant was cleared by centrifugation for 5 min at 8,000 rpm, and stored in aliquots at -85°C. The concentration of HIV-1 Gag p24 antigen in viral supernatants was measured by enzyme-linked immunosorbent assay (ELISA) (HIV-1 p24 Antigen Capture Assay; Advanced Bioscience Laboratory, Rockville, MD). The relative infectivity of recombinant viruses containing wild-type or mutant Env clones was examined, as follows. U87.CD4.CXCR4 or U87.CD4.CCR5 cells, which were seeded into a 24-well plate (3 × 104 cells per 500 μl per well) 24 h prior to the tests, were infected with recombinant viruses (10 ng of p24 antigen). U87.CD4.CXCR4 cells were used as target cells for recombinant viruses containing CXCR4-tropic (X4) or dual-tropic (X4R5) Env, whereas U87.CD4.CCR5 cells were used as target cells for the viruses containing CCR5-tropic (R5) Env. Forty-eight hours after infection, luciferase activity in infected cells was measured using the Steady Glo Luciferase assay kit (Promega, Madison, WI) with an LB960 microplate luminometer (Berthold, Bad Wildbad, Germany). Relative infectivity of the recombinant virus was calculated by comparing it with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, which was defined as 100 relative light units (RLU).
Neutralization susceptibilities of a recombinant virus to nhmAbs against the CD4bs of Env gp120, b12 (Polymun Scientific, Vienna, Austria) and VRC01 (obtained from Dr. John Mascola through the ARRRP), were examined as follows. Viral supernatants (5 ng of p24 antigen) were incubated with 2-fold serially diluted monoclonal antibody, b12 or VRC01, in 100 μl complete medium for 1 h at 37°C. U87.CD4.CXCR4 or U87.CD4.CCR5 cells, which were seeded into a 96-well plate (5 × 103 cells per 100 μl per well) 24 h prior to neutralization tests, were then incubated with the mixture of viral supernatants and the antibody. Forty-eight hours after infection, luciferase activity in infected cells was measured as described above. Percent neutralization was calculated by determining the reduction in luciferase activity in the presence of the monoclonal antibody, b12 or VRC01, compared to that in control experiments in the absence of the antibody. The IC50 of the monoclonal antibody for suppressing viral replication was calculated using a standard function of GraphPad Prism 5 software (GraphPad Software, San Diego, CA).
The binding efficiency of a recombinant virus to the monoclonal antibody, b12 was examined as follows. The antibody, b12 (5 μg) was incubated with protein G-conjugated magnetic beads, Dynabeads Protein G (0.3 mg) (Life Technologies, Lillestrom, Norway) with rotation for 24 h at 4°C in 400 μl phosphate-buffered saline (PBS), to generate b12-magnetic bead complex. After washed with PBS using the Dynal MPC-S Magnetic Particle Concentrator (Invitrogen Dynal, Oslo, Norway), the b12-magnetic bead complex was incubated with viral supernatants (2.5 ng of p24 antigen) with rotation for 24 h at 4°C in 100 μl of PBS. In a control experiment, viral supernatants containing an Env-deficient virus (2.5 ng of p24 antigen), that was generated from an env-deficient proviral construct, pNL-Luc-E-R+, was incubated with the b12-magnetic bead complex. Twenty-four hours after incubation, the virus-b12-magnetic bead complex was extensively washed with PBS and then HIV-1 Gag p24 antigen associated with the complex was measured by ELISA as described above. The percent recovery of Gag p24 antigen was calculated after subtracting the p24 antigen value associated with the virus-b12-magnetic bead complex in the control experiment using Env-deficient virus. Statistical analysis was carried out using a standard function of GraphPad Prism 5 software (GraphPad Software, San Diego, CA) with a Paired t test.
Engelman A, Cherepanov P: The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012, 10: 279-290. 10.1038/nrmicro2747.
Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ: Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science. 2011, 334: 1289-1293. 10.1126/science.1213782.
Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR: Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007, 13: 1032-1034. 10.1038/nm1624.
Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011, 333: 1633-1637. 10.1126/science.1207227.
Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O’Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010, 329: 856-861. 10.1126/science.1187659.
Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, NISC Comparative Sequencing Program, et al: Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011, 333: 1593-1602. 10.1126/science.1207532.
Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang Y, Zhu J, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010, 329: 811-817. 10.1126/science.1192819.
Clapham PR, Lu S: Vaccinology: precisely tuned antibodies nab HIV. Nature. 2011, 477: 416-417. 10.1038/477416a.
McElrath MJ, Haynes BF: Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010, 33: 542-554. 10.1016/j.immuni.2010.09.011.
Kwong PD, Mascola JR, Nabel GJ: Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol. 2013, 13: 693-701. 10.1038/nri3516.
Eroshkin AM, Leblanc A, Weekes D, Post K, Li Z, Rajput A, Butera ST, Burton DR, Godzik A: bNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res. 2014, 42: D1133-D1139. 10.1093/nar/gkt1083.
Barbas CF, Collet TA, Amberg W, Roben P, Binley JM, Hoekstra D, Cababa D, Jones TM, Williamson RA, Pilkington GR, Haigwood NL, Cabezas E, Satterthwait AC, Sanz I, Burton DR: Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. J Mol Biol. 1993, 230: 812-823. 10.1006/jmbi.1993.1203.
Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994, 266: 1024-1027. 10.1126/science.7973652.
Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994, 68: 4821-4828.
Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA: A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991, 88: 10134-10137. 10.1073/pnas.88.22.10134.
Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004, 78: 13232-13252. 10.1128/JVI.78.23.13232-13252.2004.
Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF, Burton DR, Ho DD, Moore JP: Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995, 69: 6609-6617.
Parren PW, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF, Burton DR, Mosier DE: Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS. 1995, 9: F1-F6.
Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001, 75: 8340-8347. 10.1128/JVI.75.17.8340-8347.2001.
Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP: Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003, 9: 343-346. 10.1038/nm833.
Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D: Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012, 481: 81-84.
Veselinovic M, Neff CP, Mulder LR, Akkina R: Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology. 2012, 432: 505-510. 10.1016/j.virol.2012.06.025.
Seay K, Qi X, Zheng JH, Zhang C, Chen K, Dutta M, Deneroff K, Ochsenbauer C, Kappes JC, Littman DR, Goldstein H: Mice transgenic for CD4-specific human CD4, CCR5 and cyclin T1 expression: a new model for investigating HIV-1 transmission and treatment efficacy. PLoS One. 2013, 8: e63537-10.1371/journal.pone.0063537.
Haynes BF, Montefiori DC: Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev Vaccines. 2006, 5: 347-363. 10.1586/14760518.104.22.1687.
Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011, 25: 679-689. 10.1097/QAD.0b013e328342ff93.
Arroyo MA, Phanuphak N, Krasaesub S, Sirivichayakul S, Assawadarachai V, Poltavee K, Pankam T, Ananworanich J, Paris R, Tovanabutra S, Kijak GH, McCutchan FE, Phanuphak P, Kim JH, de Souza M: HIV type 1 molecular epidemiology among high-risk clients attending the Thai Red Cross Anonymous Clinic in Bangkok, Thailand. AIDS Res Hum Retroviruses. 2010, 26: 5-12. 10.1089/aid.2009.0150.
Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M: Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand. Microbes Infect. 2009, 11: 334-343. 10.1016/j.micinf.2008.12.008.
Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009, 326: 285-289. 10.1126/science.1178746.
Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B: Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol. 2010, 6: e1000955-10.1371/journal.pcbi.1000955.
Li Y, O’Dell S, Walker LM, Wu X, Guenaga J, Feng Y, Schmidt SD, McKee K, Louder MK, Ledgerwood JE, Graham BS, Haynes BF, Burton DR, Wyatt RT, Mascola JR: Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011, 85: 8954-8967. 10.1128/JVI.00754-11.
Wu X, Zhou T, O’Dell S, Wyatt RT, Kwong PD, Mascola JR: Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol. 2009, 83: 10892-10907. 10.1128/JVI.01142-09.
Utachee P, Jinnopat P, Isarangkura-Na-Ayuthaya P, de Silva UC, Nakamura S, Siripanyaphinyo U, Wichukchinda N, Tokunaga K, Yasunaga T, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M: Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand. AIDS Res Hum Retroviruses. 2009, 25: 229-236. 10.1089/aid.2008.0232.
Utachee P, Nakamura S, Isarangkura-Na-Ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M: Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain. J Virol. 2010, 84: 4311-4320. 10.1128/JVI.02619-09.
Samleerat T, Braibant M, Jourdain G, Moreau A, Ngo-Giang-Huong N, Leechanachai P, Hemvuttiphan J, Hinjiranandana T, Changchit T, Warachit B, Suraseranivong V, Lallemant M, Barin F: Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE. J Infect Dis. 2008, 198: 868-876. 10.1086/591251.
Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL: Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol. 2008, 82: 638-651. 10.1128/JVI.01691-07.
Duenas-Decamp MJ, Peters P, Burton D, Clapham PR: Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J Virol. 2008, 82: 5807-5814. 10.1128/JVI.02585-07.
Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R: Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology. 2003, 313: 387-400. 10.1016/S0042-6822(03)00294-0.
Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, Parren PW, Mosier DE, Burton DR: Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity. 1999, 10: 431-438. 10.1016/S1074-7613(00)80043-6.
Zolla-Pazner S, Cardozo T: Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol. 2010, 10: 527-535. 10.1038/nri2801.
Mascola JR, Montefiori DC: HIV-1: nature’s master of disguise. Nat Med. 2003, 9: 393-394. 10.1038/nm0403-393.
Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393: 648-659. 10.1038/31405.
Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S: Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008, 455: 109-113. 10.1038/nature07159.
Ly A, Stamatatos L: V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol. 2000, 74: 6769-6776. 10.1128/JVI.74.15.6769-6776.2000.
Mo H, Stamatatos L, Ip JE, Barbas CF, Parren PW, Burton DR, Moore JP, Ho DD: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J Virol. 1997, 71: 6869-6874.
Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, Paxton WA: Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol. 2004, 78: 524-530. 10.1128/JVI.78.1.524-530.2004.
Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, Burke B, Cheng-Mayer C, Stamatatos L: The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol. 2005, 79: 9069-9080. 10.1128/JVI.79.14.9069-9080.2005.
Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998, 393: 705-711. 10.1038/31514.
Boonchawalit S, Jullaksorn D, Uttiyoung J, Yowang A, Krathong N, Chautrakul S, Yamashita A, Ikuta K, Roobsoong A, Kanitvittaya S, Sawanpanyalert P, Kameoka M: Molecular evolution of HIV-1 CRF01_AE Env in Thai patients. PLoS One. 2011, 6: e27098-10.1371/journal.pone.0027098.
Girard MP, Osmanov S, Assossou OM, Kieny MP: Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine. 2011, 29: 6191-6218. 10.1016/j.vaccine.2011.06.085.
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009, 361: 2209-2220. 10.1056/NEJMoa0908492.
Schiffner T, Sattentau QJ, Dorrell L: Development of prophylactic vaccines against HIV-1. Retrovirology. 2013, 10: 72-10.1186/1742-4690-10-72.
Alam SM, Liao HX, Tomaras GD, Bonsignori M, Tsao CY, Hwang KK, Chen H, Lloyd KE, Bowman C, Sutherland L, Jeffries TL, Kozink DM, Stewart S, Anasti K, Jaeger FH, Parks R, Yates NL, Overman RG, Sinangil F, Berman PW, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Karasavva N, Rerks-Ngarm S, Kim JH, Michael NL, Zolla-Pazner S, Santra S, Letvin NL, et al: Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol. 2013, 87: 1554-1568. 10.1128/JVI.00718-12.
Kijak GH, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, Kunasol P, Khamboonruang C, Thongcharoen P, Namwat C, Premsri N, Benenson M, Morgan P, Bose M, Sanders-Buell E, Paris R, Robb ML, Birx DL, De Souza MS, McCutchan FE, Michael NL, Kim JH: Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J Virol. 2013, 87: 7265-7281. 10.1128/JVI.03070-12.
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, et al: The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012, 28: 1444-1457. 10.1089/aid.2012.0103.
Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris dE, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O’Connell RJ, Ngauy V, Nitayaphan S, De Souza M, Korber B, Koup R, Bailer RT, Mascola JR, Pinter A, Montefiori D, Haynes BF, Robb ML, Rerks-Ngarm S, Michael NL, Gilbert PB, Kim JH: Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013, 8: e53629-10.1371/journal.pone.0053629.
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, et al: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012, 366: 1275-1286. 10.1056/NEJMoa1113425.
Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, DeCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, et al: Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012, 490: 417-420. 10.1038/nature11519.
Sapsutthipas S, Tsuchiya N, Pathipavanich P, Ariyoshi K, Sawanpanyalert P, Takeda N, Isarangkura-na-ayuthaya P, Kameoka M: CRF01_AE-specific neutralizing activity observed in plasma derived from HIV-1-infected Thai patients residing in northern Thailand: comparison of neutralizing breadth and potency between plasma derived from rapid and slow progressors. PLoS One. 2013, 8: e53920-10.1371/journal.pone.0053920.
Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS: Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses. 1996, 12: 1319-1328. 10.1089/aid.1996.12.1319.
Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, Hirunras K, Kitayaporn D, Kaewkangwal J, Migasena S, Sheppard HW, Li E, Chernow M, Peterson ML, Shibata R, Heyward WL, Francis DP: Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr. 2004, 37: 1160-1165. 10.1097/01.qai.0000136091.72955.4b.
Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T, Korber B: Diversity considerations in HIV-1 vaccine selection. Science. 2002, 296: 2354-2360. 10.1126/science.1070441.
Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B: Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol. 2007, 81: 4886-4891. 10.1128/JVI.01954-06.
Patel MB, Hoffman NG, Swanstrom R: Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol. 2008, 82: 903-916. 10.1128/JVI.01444-07.
McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, et al: Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011, 480: 336-343. 10.1038/nature10696.
Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA: Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science. 2013, 342: 1477-1483. 10.1126/science.1245625.
Kolchinsky P, Kiprilov E, Sodroski J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol. 2001, 75: 2041-2050. 10.1128/JVI.75.5.2041-2050.2001.
Pantophlet R, Ollmann Saphire E, Poignard P, Parren PW, Wilson IA, Burton DR: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol. 2003, 77: 642-658. 10.1128/JVI.77.1.642-658.2003.
Kinomoto M, Yokoyama M, Sato H, Kojima A, Kurata T, Ikuta K, Sata T, Tokunaga K: Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol. 2005, 79: 5996-6004. 10.1128/JVI.79.10.5996-6004.2005.
Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986, 59: 284-291.
Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005, 79: 10108-10125. 10.1128/JVI.79.16.10108-10125.2005.
Tokunaga K, Greenberg ML, Morse MA, Cumming RI, Lyerly HK, Cullen BR: Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol. 2001, 75: 6776-6785. 10.1128/JVI.75.15.6776-6785.2001.
This work was supported in part by the program of the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) by the Ministry of Education, Culture, Sports, Science and Technology of Japan. U87.CD4.CXCR4 and U87.CD4.CCR5 cell lines, subtype B env clones, QH0692.42, TRO.11, pWITO4160.33 and SC422661.8, and a human monoclonal antibody, VRC01, were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. The manuscript was proofread by Medical English Service (Kyoto, Japan).
The authors declare that they have no competing interests.
PU performed the majority of experiments, analyzed the data, designed the figures and drafted the manuscript. PI, KT, KI and NT contributed to design the study and participated in the analysis and interpretation of the data. MK designed the study and wrote the manuscript. All authors read and approved the manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Utachee, P., Isarangkura-na-ayuthaya, P., Tokunaga, K. et al. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site. Retrovirology 11, 32 (2014) doi:10.1186/1742-4690-11-32
- Human immunodeficiency virus type 1
- Envelope glycoprotein
- IgG1 b12
- Neutralizing antibody